A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Phase 1/2 Withdrawn
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
Phase 1/2 Withdrawn
Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer
Phase 1/2 Withdrawn
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
Phase 1/2 Withdrawn
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
Phase 1/2 Withdrawn
INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients
Phase 1/2 Withdrawn
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
Phase 1/2 Withdrawn
2019-101826
Phase 1/2 Withdrawn
Study of SM-88 in Advanced Cancers
Phase 1/2 Withdrawn
TOPAZ
Phase 1/2 Withdrawn
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
Phase 1/2 Withdrawn
Study of M4344 in Combination With Niraparib
Phase 1/2 Withdrawn
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
Phase 1/2 Withdrawn
A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS
Phase 1/2 Withdrawn
Chimeric Antigen Receptor-Modified T Cells for Breast Cancer
Phase 1/2 Withdrawn
GLACIER
Phase 1/2 Withdrawn
A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Phase 1/2 Withdrawn
MBC
Phase 1/2 Withdrawn
Phase I/IIa Study of Pharmacokinetics and Safety of Epidiferphaneâ„¢ and Taxanes in Breast Cancer Patients
Phase 1/2 Withdrawn
Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors
Phase 1/2 Withdrawn
A Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer That Overexpresses Functional Na/I Symporter
Phase 1/2 Withdrawn
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
Phase 1/2 Withdrawn
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
Phase 1/2 Withdrawn
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
Phase 1/2 Withdrawn
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer
Phase 1/2 Withdrawn
BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain
Phase 1/2 Withdrawn
Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab
Phase 1/2 Withdrawn
Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers
Phase 1/2 Withdrawn
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer
Phase 1/2 Withdrawn
Hydralazine as Demethylating Agent in Breast Cancer
Phase 1/2 Withdrawn
Fluorescein for Sentinel Lymph Node Biopsy (SLNB) in Breast Cancer
Phase 1/2 Withdrawn
A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer
Phase 1/2 Withdrawn
56 enrolled